Nathan Hatcher is a Senior Principal Scientist at Merck & Co., Inc. with nearly two decades of drug development experience. His laboratory focuses on biomarker discovery and clinical translation for Merck’s preclinical Neuroscience drug development pipeline and has successfully advanced pharmacodynamic biomarker assays for neurodegenerative disease targets from preclinical discovery to use in early clinical trials. In addition to preclinical drug development, Nate is active in the academic research community through grant funded collaborations and serves as an industry representative working with disease consortia to advance clinical biomarkers for patient selection, stratification and therapeutic pharmacodynamics.